- SK pharmteco invests $260 million to expand small molecule and peptide production in Sejong, South Korea.
- The new facility is expected to begin operations in 2026, with the addition of 300 employees.
SK pharmteco, a global contract development and manufacturing organization (CDMO), has announced a $260 million investment to expand its small molecule and peptide production capabilities. The new facility will be located in Sejong, South Korea, and is scheduled to begin operations by late 2026.
The plant will be the company’s fifth in South Korea and will feature eight production trains, producing tens of metric tons annually. The facility will span 135,800 square feet and include resources for early-stage clinical and commercial production. These resources will include cGMP kilo labs, a cGMP pilot plant, and advanced peptide R&D facilities. As part of this investment, SK pharmteco will also build the framework for a sixth manufacturing plant, allowing future capacity expansion.
“This expansion is a testament to our unwavering dedication to serving the evolving needs of the life sciences industry,” said Joerg Ahlgrimm, CEO of SK pharmteco.
The company plans to hire over 300 employees at the Sejong site to support this significant growth. The expansion is aimed at addressing the increasing global demand for high-quality peptides and small molecules, critical in the development of innovative therapies.
“Our new facility represents a significant investment in our future and a commitment to delivering exceptional value to our customers,” added Yongwoo Park, President of Small Molecule, Asia at SK pharmteco.
 Overview of outsourcing trends 
